AngioDynamics, Inc. (NASDAQ:ANGO) Shares Sold by Williams & Novak LLC

Williams & Novak LLC reduced its position in AngioDynamics, Inc. (NASDAQ:ANGO) by 54.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 20,085 shares of the medical instruments supplier’s stock after selling 24,280 shares during the quarter. Williams & Novak LLC owned about 0.05% of AngioDynamics worth $156,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of ANGO. Quarry LP raised its stake in AngioDynamics by 75.1% during the 2nd quarter. Quarry LP now owns 6,047 shares of the medical instruments supplier’s stock valued at $37,000 after acquiring an additional 2,594 shares during the last quarter. Mackenzie Financial Corp purchased a new stake in shares of AngioDynamics during the second quarter worth approximately $80,000. AE Wealth Management LLC purchased a new stake in shares of AngioDynamics during the second quarter worth approximately $87,000. State Board of Administration of Florida Retirement System lifted its holdings in shares of AngioDynamics by 44.1% during the first quarter. State Board of Administration of Florida Retirement System now owns 15,627 shares of the medical instruments supplier’s stock worth $92,000 after purchasing an additional 4,780 shares during the period. Finally, SG Americas Securities LLC purchased a new position in AngioDynamics in the 3rd quarter valued at $103,000. 89.43% of the stock is owned by institutional investors and hedge funds.

AngioDynamics Stock Performance

AngioDynamics stock opened at $6.10 on Tuesday. AngioDynamics, Inc. has a 1 year low of $5.26 and a 1 year high of $8.25. The firm has a 50 day moving average price of $7.44 and a 200 day moving average price of $6.64. The company has a market cap of $244.34 million, a price-to-earnings ratio of -1.26 and a beta of 0.65.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings data on Thursday, October 3rd. The medical instruments supplier reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.04. The business had revenue of $67.50 million during the quarter, compared to the consensus estimate of $67.93 million. AngioDynamics had a negative return on equity of 4.91% and a negative net margin of 61.55%. The business’s revenue for the quarter was down 14.2% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.12) EPS. Sell-side analysts predict that AngioDynamics, Inc. will post -0.41 EPS for the current year.

Analyst Ratings Changes

ANGO has been the topic of a number of analyst reports. HC Wainwright restated a “buy” rating and issued a $14.00 price target on shares of AngioDynamics in a research note on Friday. Canaccord Genuity Group decreased their target price on shares of AngioDynamics from $13.00 to $12.00 and set a “buy” rating on the stock in a research report on Friday.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.